^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Bavencio (avelumab)

    i
    Other names: MSB0010718C, PF-06834635, MSB-0010718C, COMPOUND 2055269, MSB 0010718C, PF06834635, PF 06834635
    Company:
    EMD Serono
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    6d
    A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=56, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2027 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Bavencio (avelumab)
    7d
    Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (clinicaltrials.gov)
    P1/2, N=90, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Bavencio (avelumab) • peposertib (M3814) • Xofigo (radium Ra-223 dichloride)
    9d
    Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors. (PubMed, Cancer Res Commun)
    This first-in-human study demonstrates that IT or IV VV1 administration had an acceptable safety profile as monotherapy and IV in combination with avelumab. There is preliminary antitumor activity. IT VV1 plus cemiplimab is now showing promise in the neoadjuvant setting.
    P1 data • Journal • First-in-human
    |
    IFNB1 (Interferon Beta 1)
    |
    Bavencio (avelumab) • Libtayo (cemiplimab-rwlc)
    9d
    Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (clinicaltrials.gov)
    P3, N=77, Active, not recruiting, Pfizer | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • Talzenna (talazoparib) • pemetrexed • axitinib • vidutolimod (CMP-001) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)
    12d
    Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma. (PubMed, Mayo Clin Proc Innov Qual Outcomes)
    After nivolumab discontinuation and transition to avelumab, the patient experienced complete metabolic resolution of cardiac involvement, improvement in cardiac biomarkers, and durable control of cutaneous lymphoma over more than 3 years of follow-up. This case highlights a temporal association between programmed cell death-1 blockade and atypical dissemination of cutaneous T-cell lymphoma, supported by biologic plausibility, and underscores a potential therapeutic distinction between programmed cell death-1 and programmed death ligand-1 inhibition in malignant T-cell disorders.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Opdivo (nivolumab) • Bavencio (avelumab)
    15d
    ADAM: Adjuvant Avelumab in Merkel Cell Cancer (clinicaltrials.gov)
    P3, N=101, Active, not recruiting, University of Washington | Trial primary completion date: Apr 2026 --> Jan 2029
    Trial primary completion date
    |
    Bavencio (avelumab)
    19d
    Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (clinicaltrials.gov)
    P3, N=654, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jul 2029 | Trial primary completion date: Jun 2026 --> Jul 2029
    Trial completion date • Trial primary completion date
    |
    IFNA1 (Interferon Alpha 1)
    |
    Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    19d
    Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (clinicaltrials.gov)
    P1/2, N=23, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • CD4 (CD4 Molecule) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCF (FA complementation group F) • FANCM (FA Complementation Group M) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCC (FA Complementation Group C)
    |
    Bavencio (avelumab) • berzosertib (M6620)
    1m
    Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma. (PubMed, Cancer Med)
    This exploratory Bayesian reanalysis complements the interpretation of the JAVELIN Renal 101 trial and offers a probabilistic perspective beyond a dichotomous (i.e., significant/nonsignificant) interpretation.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    sunitinib • Bavencio (avelumab) • axitinib
    1m
    Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Apr 2026 --> Jan 2027 | Trial primary completion date: Apr 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Bavencio (avelumab) • tuvusertib (M1774) • lartesertib (M4076)
    1m
    Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (clinicaltrials.gov)
    P2, N=375, Active, not recruiting, BicycleTx Limited | Phase classification: P2/3 --> P2 | N=956 --> 375 | Trial completion date: Dec 2030 --> Mar 2028 | Trial primary completion date: Dec 2030 --> Mar 2028
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Bavencio (avelumab) • zelenectide pevedotin (BT8009)
    1m
    Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case series. (PubMed, Chemotherapy)
    PBC is often considered as a subsequent treatment after EVP therapy, except in patients with FGFR gene alterations. PBC followed by avelumab maintenance therapy may represent a feasible subsequent treatment option for selected patients with mUC who achieve disease control after EVP therapy.
    Journal • PD(L)-1 Biomarker
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • Padcev (enfortumab vedotin-ejfv)